Drug Trial Radar · NCT06894212
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
538
Actual
Start
Feb 28, 2025
Primary completion
Oct 20, 2026
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Mar 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia
Conditions
- Schizophrenia
Interventions
SEP-363856Drug
tablet
PlaceboOther
tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change from baseline in Positive And Negative Syndrome Scale (PANSS) total score at Week 6Time frame: Baseline to Week 6
Locations
73 sites in 2 countries. Site status is shown where the registry gives one.
Pillar Clinical Research LLC - Bentonville Site
Bentonville, Arkansas
Pillar Clinical Research (Little Rock AR) Site
Little Rock, Arkansas
Woodland International Research Group Site
Little Rock, Arkansas
Woodland Research Northwest Site
Rogers, Arkansas
Clinical Innovations, Inc. dba CITrials (Bellflower)
Bellflower, California
ProScience Research Group Site
Culver City, California
CenExel CNS - Garden Grove (Collaborative Neuroscience Research) Site
Garden Grove, California
Synergy San Diego Site
Lemon Grove, California
Catalina Research Institute Site
Montclair, California
Clinical Innovations Inc. DBA CITrials (Riverside)
Riverside, California
Richmond Behavioral Associates LLC
Riverside, California
CNRI - San Diego LLC Site
San Diego, California
Schuster Medical Research Institute
Sherman Oaks, California
CenExel CNS - Los Alamitos (Collaborative Neuroscience Research)
Torrance, California
Galiz Research Site
Hialeah, Florida
Segal Trials - Larkin Behavioral Health - Inpatient & Early Phase Site
Hollywood, Florida
Cenexel RCA (Research Centers of America) Site
Hollywood, Florida
Premier Clinical Research Institute
Miami, Florida
D & H National Research Centers NC
Miami, Florida
Innovative Clinical Research, Inc. Site
Miami Lakes, Florida
Health Synergy Clinical Research LLC Site
West Palm Beach, Florida
Synexus Clinical Research US Inc - Atlanta
Atlanta, Georgia
CenExel ACMR (Atlanta Center for Medical Research, LLC) Site
Atlanta, Georgia
CenExel IRA (CenExcel iResearch, LLC) Site
Decatur, Georgia
Accelerated Clinical Trials in Peachtree Corners GA Site
Peachtree Corners, Georgia
Uptown Research Institute
Chicago, Illinois
Pillar Clinical Research LLC (Chicago)
Chicago, Illinois
Eastern Clinical Research Associates
New Orleans, Louisiana
Cenexel CBH (CBH Health)
Gaithersburg, Maryland
Hassman Research Institute, LLC
Marlton, New Jersey
Neuro-Behavioral Clinical Research Site
North Canton, Ohio
Community Clinical Research Inc
Austin, Texas
InSite Clinical Research
DeSoto, Texas
HD Research - Memorial Hermann Surgery Center Memorial Village
Houston, Texas
Pillar Clinical Research LLC (Richardson, TX) Site
Richardson, Texas
Wakayama Medical University Hospital
Wakayama, Japan
Hotei Hospital
Konan-shi, Aichi-ken, Japan
Seishinkai Okehazama Hospital
Toyoake-shi, Aichi-ken, Japan
Seijinkai Seinan Hospital
Hachinohe-shi, Aomori, Japan
National Hospital Organization Shimofusa Psychiatric Medical Center
Chiba, Chiba, Japan
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.